Effective February 1, 2024, Medi-Cal Rx will require prior authorization (PA) for Reyvow (lasmiditan succinate), which is used to treat migraines. PAs will be required for new and renewing prescriptions.

Alternatives not requiring a PA request are listed on the Medi-Cal Rx Contract Drugs List and include:

• Imitrex (sumatriptan)
• Amerge (naratriptan)
• Maxalt and Maxalt-MLT (rizatriptan)
• Nurtec ODT (rimegepant)
• Ubrelvy (ubrogepant)
• Ergotamine/caffeine

For more information, see the announcement.

Questions? Contact the Medi-Cal Rx Customer Service Center (CSC) at (800) 977-2273 or MediCalRxEducationOutreach@magellanhealth.com.